Whatever Happened To Industry's Interest In Ebola?
This article was originally published in Scrip
The story of the year for the biopharmaceutical industry in 2015 was most certainly the rumpus over drug prices – whether it was the uproar over the jacked up costs of older products by Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc. or the deals the new kids on the block, the proprotein convertase subtilisin/kexin 9 inhibitors, Sanofi SA's and Regeneron Pharmaceuticals Inc.'s Praluent (alirocumab) and Amgen Inc.'s Repatha (evolocumab), had to make with payers to get past the fray.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.